Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/23/24
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsGlobeNewsWire • 03/27/24
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated MelanomaGlobeNewsWire • 12/11/23
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash RunwayGlobeNewsWire • 11/28/23
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/05/23
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid TumorsGlobeNewsWire • 08/29/23
August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 08/28/23
August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since FebruarySeeking Alpha • 08/14/23
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant GliomaGlobeNewsWire • 06/22/23
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines PipelineGlobeNewsWire • 06/05/23
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK InhibitorGlobeNewsWire • 05/31/23
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23